Your browser doesn't support javascript.
loading
Development of a Humanized Antibody Targeting Extracellular HSP90α to Suppress Endothelial-Mesenchymal Transition-Enhanced Tumor Growth of Pancreatic Adenocarcinoma Cells.
Fan, Chi-Shuan; Hung, Hui-Chen; Chen, Chia-Chi; Chen, Li-Li; Ke, Yi-Yu; Yeh, Teng-Kuang; Huang, Chin-Ting; Chang, Teng-Yuan; Yen, Kuei-Jung; Chen, Chung-Hsing; Chua, Kee Voon; Hsu, John Tsu-An; Huang, Tze-Sing.
Afiliación
  • Fan CS; National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Hung HC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Chen CC; National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Chen LL; National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Ke YY; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Yeh TK; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Huang CT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Chang TY; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Yen KJ; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Chen CH; National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Chua KV; National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Hsu JT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Huang TS; Anbogen Therapeutics, Taipei 11571, Taiwan.
Cells ; 13(13)2024 Jul 04.
Article en En | MEDLINE | ID: mdl-38994997
ABSTRACT
Extracellular HSP90α (eHSP90α) is a promoter of tumor development and malignant progression. Patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC), have generally shown 5~10-fold increases in serum/plasma eHSP90α levels. In this study, we developed a humanized antibody HH01 to target eHSP90α and evaluated its anticancer efficacy. HH01, with novel complementarity-determining regions, exhibits high binding affinity toward HSP90α. It recognizes HSP90α epitope sites 235AEEKEDKEEE244 and 251ESEDKPEIED260, with critical amino acid residues E237, E239, D240, K241, E253, and K255. HH01 effectively suppressed eHSP90α-induced invasive and spheroid-forming activities of colorectal cancer and PDAC cell lines by blocking eHSP90α's ligation with the cell-surface receptor CD91. In mouse models, HH01 potently inhibited the tumor growth of PDAC cell grafts/xenografts promoted by endothelial-mesenchymal transition-derived cancer-associated fibroblasts while also reducing serum eHSP90α levels, reflecting its anticancer efficacy. HH01 also modulated tumor immunity by reducing M2 macrophages and reinvigorating immune T-cells. Additionally, HH01 showed low aggregation propensity, high water solubility, and a half-life time of >18 days in mouse blood. It was not cytotoxic to retinal pigmented epithelial cells and showed no obvious toxicity in mouse organs. Our data suggest that targeting eHSP90α with HH01 antibody can be a promising novel strategy for PDAC therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Proteínas HSP90 de Choque Térmico / Anticuerpos Monoclonales Humanizados Límite: Animals / Humans Idioma: En Revista: Cells Año: 2024 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Proteínas HSP90 de Choque Térmico / Anticuerpos Monoclonales Humanizados Límite: Animals / Humans Idioma: En Revista: Cells Año: 2024 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Suiza